Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 51

1.

High-dose tirofiban pretreatment reduces the need for bail-out study medication in patients with ST-segment elevation myocardial infarction: results of a subgroup analysis of the On-TIME 2 trial.

Hermanides RS, Heestermans AA, Ten Berg JM, Gosselink AT, Ottervanger JP, van Houwelingen KG, Kolkman JJ, Stella PR, Dill T, Hamm C, van 't Hof AW.

Heart. 2011 Jan;97(2):106-11. doi: 10.1136/hrt.2010.194951. Epub 2010 Oct 20.

PMID:
20962338
2.

Marked reduction of early stent thrombosis with pre-hospital initiation of high-dose Tirofiban in ST-segment elevation myocardial infarction.

Heestermans AA, Van Werkum JW, Hamm C, Dill T, Gosselink AT, De Boer MJ, Van Houwelingen G, Hoorntje JC, Koopmans PC, Ten Berg JM, Van 't Hof AW.

J Thromb Haemost. 2009 Oct;7(10):1612-8. doi: 10.1111/j.1538-7836.2009.03573.x. Epub 2009 Aug 11.

3.

Effect of early, pre-hospital initiation of high bolus dose tirofiban in patients with ST-segment elevation myocardial infarction on short- and long-term clinical outcome.

ten Berg JM, van 't Hof AW, Dill T, Heestermans T, van Werkum JW, Mosterd A, van Houwelingen G, Koopmans PC, Stella PR, Boersma E, Hamm C; On-TIME 2 Study Group.

J Am Coll Cardiol. 2010 Jun 1;55(22):2446-55. doi: 10.1016/j.jacc.2009.11.091.

4.

Prehospital high-dose tirofiban in patients undergoing primary percutaneous intervention. The AGIR-2 study.

El Khoury C, Dubien PY, Mercier C, Belle L, Debaty G, Capel O, Perret T, Savary D, Serre P, Bonnefoy E; AGIR-2 Investigators.

Arch Cardiovasc Dis. 2010 May;103(5):285-92. doi: 10.1016/j.acvd.2010.04.005. Epub 2010 Jun 17.

5.

IIb or Not IIb: is there a place for pre-hospital tirofiban in ST-segment elevation myocardial infarction patients?

Waksman R.

J Am Coll Cardiol. 2010 Jun 1;55(22):2456-8. doi: 10.1016/j.jacc.2009.12.058. No abstract available.

6.

Platelet inhibition by increased tirofiban dosing during primary coronary angioplasty for ST elevation myocardial infarction.

Kralisz P, Dobrzycki S, Nowak K, Kochman W, Gajewska-Bachórzewska H, Gugała K, Mezyński G, Prokopczuk P, Zuk J, Korecki J, Poniatowski B, Musiał W.

Kardiol Pol. 2004 May;60(5):459-67. English, Polish.

PMID:
15247961
7.

Clinical benefits of adjunctive tirofiban therapy in patients with acute ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention.

Shen J, Zhang Q, Zhang RY, Zhang JS, Hu J, Yang ZK, Zheng AF, Zhang X, Shen WF.

Coron Artery Dis. 2008 Jun;19(4):271-7. doi: 10.1097/MCA.0b013e3282f487e0.

PMID:
18480672
9.
10.

Effect of tirofiban before primary angioplasty on initial coronary flow and early ST-segment resolution in patients with acute myocardial infarction.

Cutlip DE, Ricciardi MJ, Ling FS, Carrozza JP Jr, Dua V, Garringer J, Giri S, Caputo RP.

Am J Cardiol. 2003 Oct 15;92(8):977-80.

PMID:
14556878
12.

Clopidogrel pretreatment in ST-elevation myocardial infarction patients transferred for percutaneous coronary intervention.

Larson DM, Duval S, Sharkey SS, Solie C, Tschautscher C, Lips DL, Burke MN, Steinhubl S, Henry TD.

Am Heart J. 2010 Jul;160(1):202-7. doi: 10.1016/j.ahj.2010.04.018.

PMID:
20598993
13.

Intensifying platelet inhibition with tirofiban in poor responders to aspirin, clopidogrel, or both agents undergoing elective coronary intervention: results from the double-blind, prospective, randomized Tailoring Treatment with Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel study.

Valgimigli M, Campo G, de Cesare N, Meliga E, Vranckx P, Furgieri A, Angiolillo DJ, Sabatè M, Hamon M, Repetto A, Colangelo S, Brugaletta S, Parrinello G, Percoco G, Ferrari R; Tailoring Treatment With Tirofiban in Patients Showing Resistance to Aspirin and/or Resistance to Clopidogrel (3T/2R) Investigators.

Circulation. 2009 Jun 30;119(25):3215-22. doi: 10.1161/CIRCULATIONAHA.108.833236. Epub 2009 Jun 15.

14.

The additive value of tirofiban administered with the high-dose bolus in the prevention of ischemic complications during high-risk coronary angioplasty: the ADVANCE Trial.

Valgimigli M, Percoco G, Barbieri D, Ferrari F, Guardigli G, Parrinello G, Soukhomovskaia O, Ferrari R.

J Am Coll Cardiol. 2004 Jul 7;44(1):14-9.

15.

Randomized, double-blind, placebo-controlled dose-ranging study of tirofiban (MK-383) platelet IIb/IIIa blockade in high risk patients undergoing coronary angioplasty.

Kereiakes DJ, Kleiman NS, Ambrose J, Cohen M, Rodriguez S, Palabrica T, Herrmann HC, Sutton JM, Weaver WD, McKee DB, Fitzpatrick V, Sax FL.

J Am Coll Cardiol. 1996 Mar 1;27(3):536-42.

16.

The golden hour of prehospital reperfusion with triple antiplatelet therapy: a sub-analysis from the Ongoing Tirofiban in Myocardial Evaluation 2 (On-TIME 2) trial early initiation of triple antiplatelet therapy.

Heestermans T, van 't Hof AW, ten Berg JM, van Werkum JW, Boersma E, Mosterd A, Stella PR, van Zoelen AB, Gosselink AT, Kochman W, Dill T, Koopmans PC, van Houwelingen G, Zijlstra F, Hamm C.

Am Heart J. 2010 Dec;160(6):1079-84. doi: 10.1016/j.ahj.2010.08.039.

PMID:
21146661
17.

Prehospital triple antiplatelet therapy in patients with acute ST elevation myocardial infarction leads to better platelet aggregation inhibition and clinical outcome than dual antiplatelet therapy.

Smit JJ, van Werkum JW, ten Berg J, Slingerland R, Ottervanger JP, Heestermans T, Dill T, Hamm C, van 't Hof AW; Ongoing Tirofiban in Myocardial Infarction Evaluation (On-TIME) trial investigators.

Heart. 2010 Nov;96(22):1815-20. doi: 10.1136/hrt.2010.201889. Epub 2010 Oct 3.

PMID:
20889993
18.

Effect of platelet glycoprotein IIb/IIIa receptor blockade with tirofiban on adverse cardiac events in women with unstable angina/non-ST-elevation myocardial infarction (PRISM-PLUS Study).

Huynh T, Theroux P, Snapinn S, Wan Y; Montreal General Hospital, Montreal, Quebec, Canada. thao.huynh@muhc.mcgill.ca.

Am Heart J. 2003 Oct;146(4):668-73.

PMID:
14564321
19.

Facilitated reperfusion with prehospital glycoprotein IIb/IIIa inhibition: predictors of complete ST-segment resolution before primary percutaneous coronary intervention in the On-TIME 2 trial: correlates of reperfusion before primary PCI.

Heestermans T, Suryapranata H, ten Berg JM, Mosterd A, Gosselink AT, Kochman W, Dill T, van Houwelingen G, Kolkman E, van Werkum JW, Zijlstra F, Hamm C, van 't Hof AW.

J Electrocardiol. 2011 Jan-Feb;44(1):42-8. doi: 10.1016/j.jelectrocard.2010.09.010.

PMID:
21168000
20.

Tirofiban for myocardial infarction.

Juwana YB, Suryapranata H, Ottervanger JP, van 't Hof AW.

Expert Opin Pharmacother. 2010 Apr;11(5):861-6. doi: 10.1517/14656561003690005. Review.

PMID:
20210689

Supplemental Content

Support Center